Copyright
©The Author(s) 2023.
World J Clin Cases. Mar 16, 2023; 11(8): 1753-1760
Published online Mar 16, 2023. doi: 10.12998/wjcc.v11.i8.1753
Published online Mar 16, 2023. doi: 10.12998/wjcc.v11.i8.1753
1 yr survivor patients, (n = 113) | 1 yr non-survivor patients, (n = 14) | P value | |
Serum sFasL (pg/mL) - median (p 25-75) | 85 (44-382) | 477 (269-496) | < 0.001 |
Age of liver donor (yr) - median (p 25-75) | 52 (35-64) | 62 (49-73) | 0.049 |
Age of liver recipient (yr) - median (p 25-75) | 59 (52-62) | 56 (53-62) | 0.88 |
Serum alpha-fetoprotein (ng/dL) - median (p 25-75) | 8 (4-37) | 13 (5-180) | 0.36 |
MELD score - median (p 25-75) | 15 (12-18) | 16 (14-18) | 0.78 |
Nodules size (cm) - median (p 25-75) | 3.0 (2.0-3.5) | 2.8 (1.6-4.3) | 0.94 |
Protein (g/dL) - median (p 25-75) | 6.7 (6.0-7.1) | 6.7 (5.7-7.7) | 0.83 |
Leukocytes (count/mm3) - median (p 25-75) | 4800 (3590-6200) | 4940 (3490-7920) | 0.60 |
Albumin (g/dL) - median (p 25-75) | 3.3 (2.9-4.1) | 3.3 (2.9-4.2) | 0.91 |
Creatinine (mg/dL) - median (p 25-75) | 0.9 (0.8-1.1) | 1.0 (0.8-1.1) | 0.43 |
BMI (kg/m2) - median (p 25-75) | 27.6 (24.5-30.0) | 28.1 (23.1-31.1) | 0.80 |
Gender female - n (%) | 18 (15.9) | 0 | 0.11 |
Portal hypertension - n (%) | 77 (68.1) | 10 (71.4) | 0.80 |
Child-Pugh score - n (%) | 0.47 | ||
A | 53 (46.9) | 9 (64.3) | |
B | 34 (30.1) | 3 (21.4) | |
C | 26 (23.0) | 2 (14.3) | |
Multinodular tumor- n (%) | 33 (29.2) | 5 (35.7) | 0.62 |
Macrovascular invasion - n (%) | 7 (6.2) | 0 | 0.34 |
Microvascular invasion - n (%) | 26 (23.0) | 3 (21.4) | 0.89 |
Infiltration - n (%) | 38 (33.6) | 3 (21.4) | 0.36 |
Inside Milan criteria previously to LT - n (%) | 108 (95.6) | 13 (92.9) | 0.65 |
Inside Milan criteria after LT - n (%) | 97 (85.8) | 10 (71.4) | 0.16 |
Treatment previously to LT - n (%) | 62 (54.9) | 10 (71.4) | 0.24 |
Transplantation technique – n (%) | 0.63 | ||
By-pass | 41 (36.3) | 6 (42.9) | |
Piggy back | 72 (63.7) | 8 (57.1) | |
Degree of tumor differentiation – n (%) | 0.51 | ||
Well | 83 (73.5) | 11 (78.6) | |
Moderate | 27 (23.9) | 2 (14.3) | |
Poor | 3 (2.7) | 1 (7.1) |
Odds ratio | 95% confidence interval | P value | |
Age of liver donor (age) | 1.044 | 1.001-1.088 | 0.045 |
Serum sFasL levels (pg/mL) | 1.006 | 1.003-1.010 | 0.001 |
- Citation: Lorente L, Rodriguez ST, Sanz P, González-Rivero AF, Pérez-Cejas A, Padilla J, Díaz D, González A, Martín MM, Jiménez A, Cerro P, Portero J, Barrera MA. Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations . World J Clin Cases 2023; 11(8): 1753-1760
- URL: https://www.wjgnet.com/2307-8960/full/v11/i8/1753.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i8.1753